MAP2K7 and neoplasm: Conversely, NRAS Q61 tumors are seen to achieve tumor control by having significant synergy (high Bliss excess) in drug combinations that leverage partial single-agent MEK inhibition in the 20 or, even better, 40 mg QD regimen, which combine well with doses as low as 50 mg QD and 100 mg BID of Belvarafenib.